Citius Oncology, Inc. (CTOR) Income Statement
CTOR FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsCTOR revenue and net income
CTOR growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CTOR quarterly EPS vs estimates
Citius Oncology beat the analyst EPS estimate in 2 of the last 8 quarters.
CTOR income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research & development | $6.4M | $4.9M | $4.2M | $6.9M | — |
| Sales, general & admin | $17.1M | $15.6M | $7.9M | $2.9M | — |
| Total operating expenses | $23.5M | $20.6M | $12.1M | $9.7M | — |
| Operating income | −$23.5M | −$20.6M | −$12.1M | −$9.7M | — |
| Interest income | $36,373 | $0 | — | — | — |
| Interest expense | $218,032 | $0 | — | — | — |
| Income before taxes | −$23.7M | −$20.6M | −$12.1M | −$9.7M | −$10,113 |
| Income taxes | $1.1M | $576,000 | $576,000 | $1.2M | — |
| Net income | −$24.8M | −$21.1M | −$12.7M | −$10.9M | −$10,113 |
| EBITDA | −$23.5M | −$20.6M | −$12.1M | −$4.9M | −$10,110 |
| EPS (diluted) | −$0.34 | −$0.08 | $0.20 | −$0.12 | −$0.01 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $2.2M | $328,878 | $789,208 | — | $0 | $0 | $0 | — | — | — | — | — |
| Gross profit | −$718,367 | $1.3M | $3.2M | — | $0 | $0 | $0 | — | — | — | — | — |
| Research & development | $218,496 | $1.1M | $1.0M | $1.1M | $938,277 | $3.1M | $1.3M | $1.3M | $1.1M | $1.3M | $1.1M | $1.2M |
| Sales, general & admin | $7.8M | $27.2M | $6.8M | $3.6M | $4.0M | $4.3M | $5.1M | $5.4M | $3.5M | $3.3M | $3.4M | $3.9M |
| Total operating expenses | $8.0M | $30.0M | $8.4M | $4.7M | $4.9M | $7.5M | $6.4M | $6.7M | $4.6M | $4.7M | $4.6M | $5.0M |
| Operating income | −$8.7M | −$28.6M | −$5.3M | −$4.7M | −$4.9M | −$7.5M | −$6.4M | −$6.7M | −$4.6M | −$4.7M | −$4.6M | −$5.0M |
| Interest income | $96,848 | $43,721 | $28,288 | — | $0 | $0 | $0 | — | — | — | — | — |
| Interest expense | $411,224 | $33,031 | $45,841 | $57,277 | $160,755 | $0 | $0 | — | — | — | — | — |
| Income before taxes | −$9.0M | −$26.8M | −$5.3M | −$4.7M | −$5.1M | −$7.5M | −$6.4M | −$6.7M | −$4.6M | −$4.7M | −$4.6M | −$5.0M |
| Income taxes | −$107,347 | −$231,210 | $264,240 | $264,240 | $264,240 | $264,240 | $264,240 | $144,000 | $144,000 | $144,000 | $144,000 | $144,000 |
| Net income | −$8.9M | −$26.6M | −$5.5M | −$5.0M | −$5.4M | −$7.7M | −$6.7M | −$6.8M | −$4.8M | −$4.8M | −$4.7M | −$5.2M |
| EBITDA | −$7.0M | −$26.8M | −$4.7M | −$4.7M | −$4.9M | −$7.5M | −$6.4M | −$6.7M | −$4.6M | −$4.7M | −$4.6M | $157,943 |
| EPS (diluted) | −$0.08 | −$0.27 | −$0.06 | −$0.06 | −$0.08 | −$0.11 | −$0.09 | −$0.31 | $0.04 | $0.07 | $0.12 | $0.02 |
| Gross margin | −48.1% | 80.3% | 80.0% | — | — | — | — | — | — | — | — | — |
| Operating margin | −583.5% | −1,716.2% | −133.2% | — | — | — | — | — | — | — | — | — |
| Net margin | −597.4% | −1,596.0% | −140.3% | — | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CTOR's financial statements (latest annual report filed September 30, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CTOR financial results
Citius Oncology reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $24.8 million. Diluted earnings per share came to −$0.34.
See the CTOR stock overview for the latest quote and news, or the CTOR chart for price history and technical indicators.
CTOR income statement FAQ
Does Citius Oncology have revenue?
Citius Oncology reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Citius Oncology profitable?
No. Citius Oncology reported a net loss of $24.8 million in fiscal 2025.
How much does Citius Oncology spend on research and development?
Citius Oncology spent $6.4 million on research and development in fiscal 2025.
What are Citius Oncology's earnings per share?
Citius Oncology earned $-0.34 per diluted share in fiscal 2025, compared with $-0.08 a year earlier.
When does Citius Oncology's fiscal year end?
Citius Oncology's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on September 30, 2025.